‘Dream scenario’ expands Synaffix’ scope
With the acquisition by Lonza, Dutch bioconjugation company Synaffix starts another another new chapter. ‘This creates interesting opportunities to really boost our R&D and scale-up.’
Want to read more?
Create a free account today!
- Gain access to all our content on chemistry, life sciences and process technology;
- Get our weekly newsletter so you never miss a story.
As a member of the KNCV, KVCV, NBV, or NVBMB you have unlimited access. Log in here.
